drugset / Trial / NCT06883630

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

NCT06883630

Phase 1 Active not recruiting 121 enrolled RemeGen Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer

Timeline

Start
2025-03-13
Primary completion
2026-08-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject RC148 Unknown
Background Carboplatin Small molecule
Background Paclitaxel Small molecule
Background Pemetrexed Small molecule